From multi-omics complexity to translational insights
We integrate deep immune profiling with AI-powered translational insights to reveal the mechanisms underlying health, disease and therapeutic response.
IMMUNASYST provides computational deep immune profiling of health and disease through multi-omics integration, combining mechanistic systems IMMUNology with the SYSTematic orchestration of intelligent AI agents - like a coordinated immune response.
Our specialization runs through infectious disease, oncology, and autoimmunity — yet systems biology honors no boundaries, reaching across virtually any condition where mechanism matters.
The work is collaborative by design. You bring the disease area, cohort, and clinical context. We bring systems immunology, rigorous statistics, and AI-enabled translational analysis to turn complex data into mechanistically grounded, clinically testable insights.
We integrate a diverse range of omics with patient metadata and clinical outcomes.
We reason across layers and resolve them into translational insights you can act on.
Omics inputs
Proteomics
Metabolomics
Microbiome
Flow cytometry
Transcriptomics
Spatial
ATAC-seq
Translational outputs
Patient metadata & Clinical outcomes
Mechanistic hypotheses
Functional validation experimental design
Biomarker candidates
Druggable targets
Patient stratification for precision medicine
Clinical trial design
Built on scientific partnership
IMMUNASYST has collaborated with leading academic labs and institutions to advance their research, and partnered with established biopharma to accelerate therapeutic drug development.
Beyond the analysis, we carry a study from initiation to publication — manuscript writing support, plus the data that turns grant submissions into funded science.
IMMUNASYST joins your study as an embedded scientific collaborator. We help shape the scientific question, reason across every omics layer, derive data-driven insights and stay until the biology hold together as a mechanism, not a list of significant hits!
Founder and CEO
Aarthi Talla
Aarthi Talla is a computational biologist with over 15 years of experience across infectious disease, oncology, cancer immunotherapy response, and autoimmune disorders. Her work spans Case Western Reserve University's School of Medicine, the Vaccine and Gene Therapy Institute of Florida, the Georgia Institute of Technology, Emory School of Medicine, and the Allen Institute for Immunology — where she chaired COVID-19 research at the height of the pandemic, becoming a leading voice on the heterogeneous immune responses to SARS-CoV-2, particularly long COVID.
Her research has earned first-author publications in top-tier journals including Nature Medicine, Cell, Nature Communications, and The Journal of Clinical Investigation, often built on integrative multi-omics analysis. She is also a named inventor on patents for "Long-lived T cells for treating HIV infection" and "Molecular signatures of long-term COVID-19."
Collaborating with world-renowned scientists, she kept meeting the same divide: abundant data, but too little of the balanced expertise needed to analyze and interpret it — the gap between bioinformaticians and immunologists. That divide led her to found IMMUNASYST, built from her work with world-class assays and cutting-edge technology, alongside leading immunologists, to bridge it and serve scientists' research and therapeutic needs.
Since starting IMMUNASYST, she has partnered with leading academic institutions and biopharma: studying responses to cancer immunotherapies such as anti-PD-1, mechanisms of HIV elite control and non-response, the contribution of aging to vaccine responses, targets driving anti-tumor activity in cancers like NSCLC and CRC, and therapeutic targets for intestinal repair in IBD, to name a few. She continues to pursue collaborations that deepen our understanding of health and disease, and ultimately improve patients' lives.
Start a collaboration
Tell us about your dataset, disease area and your scientific goals.
aarthitalla@immunasyst.com